Post by
HarryGluten on Nov 05, 2021 10:37am
MDNA competitor NKTR reported earnings
nktr reported earnings yesterday. Stock down 20%+ as market not liking some early data results from ph1/ph2 keytruda combo + their main drug IL-2 BEMPEG NKTR 214 for lung cancer (propel); recall that nktr is in ph3 clinical trials for all same indications as $mdna, but all their ph3 trials are in combo with big pharma WITH checkpoint inhibitor. NKTR 214 did NOT show monotherapy efficacy in ph2 trials. This early lung trial is yet another data point showing potential poor performance in trials. They are set to post results of combo trials next year for various indications. $mdna still very much in the race folks. If MDNA shows strong biomarker and safety data in December 2021 and then show monotherapy efficacy in 1st half 2022, this is going to be a homerun.
Trading wise, I think there is strong retail selling as $mdna has very little insitutional investors of size. Recall CEO owns over 30% of stock. I think we will continue to see retail tax loss selling up to biomarker/safety results , but appears that there are big block buyers. New institutions? Assuming mdna 11 biomarker and safety results strong in December, there will be a big rally in December and January as investors build positions for 2022 and take advantage of how beaten down the stock is.